The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
A successful therapy is presented using the antiplatelet agent abciximab, alone, in an ST-segment elevation acute myocardial infarction. The patient was treated in a center with permanent catheterization facilities. Clinical trials are necessary to validate the efficacy and the cost-effectiveness of this clinical decision and therapeutic option.
Mesquita
A
A
Cardiology Division, Hospital de Santa Cruz, Av. Prof. Reynaldo dos Santos, 2795 Carnaxide, Portugal.
Baptista
J
J
Palos
J
J
Seabra-Gomes
R
R
D000077284:Abciximab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017023:Coronary Angiography; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab